JP2025013884A5 - - Google Patents

Download PDF

Info

Publication number
JP2025013884A5
JP2025013884A5 JP2024182581A JP2024182581A JP2025013884A5 JP 2025013884 A5 JP2025013884 A5 JP 2025013884A5 JP 2024182581 A JP2024182581 A JP 2024182581A JP 2024182581 A JP2024182581 A JP 2024182581A JP 2025013884 A5 JP2025013884 A5 JP 2025013884A5
Authority
JP
Japan
Prior art keywords
nucleotide sequence
foxp3
homology
gene
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024182581A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025013884A (ja
JP7844582B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2019/029082 external-priority patent/WO2019210042A1/en
Application filed filed Critical
Publication of JP2025013884A publication Critical patent/JP2025013884A/ja
Publication of JP2025013884A5 publication Critical patent/JP2025013884A5/ja
Priority to JP2026060213A priority Critical patent/JP2026108825A/ja
Application granted granted Critical
Publication of JP7844582B2 publication Critical patent/JP7844582B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024182581A 2018-04-27 2024-10-18 遺伝子編集されたcd34+細胞におけるfoxp3の発現 Active JP7844582B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026060213A JP2026108825A (ja) 2018-04-27 2026-04-01 遺伝子編集されたcd34+細胞におけるfoxp3の発現

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862663545P 2018-04-27 2018-04-27
US62/663,545 2018-04-27
PCT/US2019/029082 WO2019210042A1 (en) 2018-04-27 2019-04-25 Expression of foxp3 in edited cd34+ cells
JP2020560400A JP7575950B2 (ja) 2018-04-27 2019-04-25 遺伝子編集されたcd34+細胞におけるfoxp3の発現

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020560400A Division JP7575950B2 (ja) 2018-04-27 2019-04-25 遺伝子編集されたcd34+細胞におけるfoxp3の発現

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026060213A Division JP2026108825A (ja) 2018-04-27 2026-04-01 遺伝子編集されたcd34+細胞におけるfoxp3の発現

Publications (3)

Publication Number Publication Date
JP2025013884A JP2025013884A (ja) 2025-01-28
JP2025013884A5 true JP2025013884A5 (enExample) 2025-04-10
JP7844582B2 JP7844582B2 (ja) 2026-04-13

Family

ID=68294731

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020560400A Active JP7575950B2 (ja) 2018-04-27 2019-04-25 遺伝子編集されたcd34+細胞におけるfoxp3の発現
JP2024182581A Active JP7844582B2 (ja) 2018-04-27 2024-10-18 遺伝子編集されたcd34+細胞におけるfoxp3の発現
JP2026060213A Pending JP2026108825A (ja) 2018-04-27 2026-04-01 遺伝子編集されたcd34+細胞におけるfoxp3の発現

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020560400A Active JP7575950B2 (ja) 2018-04-27 2019-04-25 遺伝子編集されたcd34+細胞におけるfoxp3の発現

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026060213A Pending JP2026108825A (ja) 2018-04-27 2026-04-01 遺伝子編集されたcd34+細胞におけるfoxp3の発現

Country Status (9)

Country Link
US (2) US11713459B2 (enExample)
EP (1) EP3784690A4 (enExample)
JP (3) JP7575950B2 (enExample)
CN (1) CN112218882A (enExample)
AU (2) AU2019261438B2 (enExample)
CA (1) CA3091688A1 (enExample)
IL (1) IL277039A (enExample)
SG (1) SG11202007878UA (enExample)
WO (1) WO2019210042A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3042179A1 (en) 2016-10-31 2018-05-03 Seattle Children's Hospital (dba Seattle Children's Research Institute) Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene
JP7575949B2 (ja) 2018-04-27 2024-10-31 シアトル チルドレンズ ホスピタル ディー/ビー/エイ シアトル チルドレンズ リサーチ インスティテュート 遺伝子編集t細胞におけるヒトfoxp3の発現
SG11202007878UA (en) * 2018-04-27 2020-09-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Expression of foxp3 in edited cd34+ cells
AU2020209687A1 (en) * 2019-01-18 2021-07-29 Osaka University Composition for use in treating dystrophic epidermolysis bullosa
JP2022533713A (ja) 2019-05-21 2022-07-25 サンガモ セラピューティクス, インコーポレイテッド 調節性t細胞における制御された導入遺伝子発現
EP3980035A4 (en) 2019-06-07 2023-08-23 The Board Of Trustees Of The Leland Stanford Junior University GENETICALLY MODIFIED CD4+ T LYMPHOCYTES FOR USE IN TREG-BASED IMMUNOTHERAPY
AU2020304057A1 (en) * 2019-06-27 2022-01-27 Benaroya Research Institute At Virginia Mason Artificial antigen-specific immunoregulatory t (airt) cells
CA3160113A1 (en) 2019-11-08 2021-05-14 Sangamo Therapeutics, Inc. Generation of engineered regulatory t cells
WO2021144692A1 (en) * 2020-01-14 2021-07-22 Crispr Therapeutics Ag Methods for increased efficiency of homology-directed repair
EP4103591A4 (en) 2020-02-13 2024-09-04 The Board of Trustees of the Leland Stanford Junior University Crispr-based foxp3 gene engineered t cells and hematopoietic stem cell precursors to treat ipex syndrome patients
TW202233830A (zh) * 2020-10-27 2022-09-01 美商Pact製藥公司 使用下一代工程化t細胞療法治療癌症之組合物及方法
CN112851794B (zh) * 2021-02-04 2023-05-23 苏州铂维生物科技有限公司 一种基于cd271的抗原表位及其应用
GB202113674D0 (en) 2021-09-24 2021-11-10 Reflection Therapeutics Ltd Targeted cell therapies
GB202113673D0 (en) 2021-09-24 2021-11-10 Reflection Therapeutics Ltd Targeted cell therapies

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100996016B1 (ko) 2000-09-20 2010-11-22 밀리포어 코포레이션 폴리뉴클레오티드
US7507542B2 (en) 2001-05-08 2009-03-24 Ucb Sa Method for regulating immune function using the FOXP3 protein
GB0614536D0 (en) 2006-07-21 2006-08-30 Metcalfe Susan M Methods of controlling cellular response to LIF
WO2008066784A2 (en) * 2006-11-27 2008-06-05 Ludwig Institute For Cancer Research Expression of foxp3 by cancer cells
PT2126054T (pt) 2007-01-31 2016-10-12 Yeda Res & Dev Células t reguladoras geneticamente modificadas, redirecionadas e sua utilização na supressão de doenças inflamatórias e autoimunitárias
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
US20110123502A1 (en) 2007-02-21 2011-05-26 Barry Simon C Method for obtaining treg-cells
US8158596B2 (en) 2007-05-11 2012-04-17 The Regents Of The University Of Michigan Materials and methods for FOXP3 tumor suppression
US8846308B2 (en) 2007-06-08 2014-09-30 The Trustees Of The University Of Pennsylvania Method for identifying immune response modulators
JP2011503232A (ja) 2007-11-20 2011-01-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫応答の調節
EP2279030A2 (en) 2008-03-03 2011-02-02 Fabio Grassi Method of modulating t cell-dependent immune responses
US8772028B2 (en) * 2008-11-07 2014-07-08 Sunnybrook Health Sciences Centre CD34+CD7+CD5+CD1a-human progenitor T-cells produced in vitro and methods of using
WO2012018930A1 (en) 2010-08-03 2012-02-09 University Of Miami Methods of isolating and expanding human t regulatory cells and uses thereof for cellular therapy
WO2014180943A1 (en) 2013-05-08 2014-11-13 Vib Vzw Mcl-1 as critical regulator of foxp3+ regulatory t cell survival, and use thereof to treat severe immune disorders
CA2912375C (en) 2013-05-13 2023-03-14 Cellectis Methods for engineering highly active t cell for immunotherapy
EP2997134B1 (en) * 2013-05-14 2020-06-24 Board of Regents, The University of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
JP6608807B2 (ja) 2013-05-29 2019-11-20 セレクティス Rnaガイドcasヌクレアーゼ系を用いることによって免疫療法のためにt細胞を操作するための方法
DK3105317T3 (en) 2014-02-14 2019-01-14 Cellectis Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells
EP3119897A1 (en) 2014-03-21 2017-01-25 Cellectis Engineering mammalian genome using dna-guided argonaute interference systems (dais)
KR101835554B1 (ko) 2014-06-24 2018-04-19 서울대학교 산학협력단 C/ebp를 포함하는 유도성 t 조절세포 분화촉진 또는 안정화 조성물 및 방법
AU2016206870B2 (en) 2015-01-12 2022-02-17 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
US20190388469A1 (en) 2015-01-30 2019-12-26 The Regents Of The University Of California Protein delivery in primary hematopoietic cells
EP3294342A4 (en) 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
EP3448995A1 (en) 2016-04-25 2019-03-06 Universität Basel Allele editing and applications thereof
EP3497221A4 (en) 2016-08-10 2020-02-05 Duke University COMPOSITIONS, SYSTEMS AND METHODS FOR PROGRAMMING IMMUNE CELL FUNCTION BY TARGETED GENE REGULATION
EP3500696A4 (en) 2016-08-16 2020-04-08 Bluebird Bio, Inc. VARIANTS OF IL-10 ALPHA RECEPTOR HOMING ENDONUCLEASE, COMPOSITIONS AND METHODS OF USE
WO2018073391A1 (en) 2016-10-19 2018-04-26 Cellectis Targeted gene insertion for improved immune cells therapy
EP3532075A4 (en) * 2016-10-27 2020-07-08 Intima Bioscience, Inc. VIRAL METHODS OF MANUFACTURING GENETICALLY MODIFIED CELLS
CA3042179A1 (en) 2016-10-31 2018-05-03 Seattle Children's Hospital (dba Seattle Children's Research Institute) Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene
CA3045667A1 (en) 2016-12-13 2018-06-21 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
CN109790518A (zh) 2017-05-08 2019-05-21 中国科学院动物研究所 经修饰的t细胞、其制备方法及用途
WO2019040655A1 (en) 2017-08-22 2019-02-28 The Regents Of The University Of California LENTIVIRAL VECTORS EXPRESSING FOXP3 IN HEMATOPOIETIC STEM CELLS TO TREAT IMMUNITY DEFICIENCIES AND AUTOIMMUNE DISEASES
JP7575949B2 (ja) 2018-04-27 2024-10-31 シアトル チルドレンズ ホスピタル ディー/ビー/エイ シアトル チルドレンズ リサーチ インスティテュート 遺伝子編集t細胞におけるヒトfoxp3の発現
SG11202007878UA (en) * 2018-04-27 2020-09-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Expression of foxp3 in edited cd34+ cells
WO2019241549A1 (en) 2018-06-15 2019-12-19 A2 Biotherapeutics, Inc. Foxp3-expressing car-t regulatory cells

Similar Documents

Publication Publication Date Title
JP2025013879A5 (enExample)
JP2020518276A5 (enExample)
JP2021526853A5 (enExample)
JP7844582B2 (ja) 遺伝子編集されたcd34+細胞におけるfoxp3の発現
Li et al. Adenovirus vectors in hematopoietic stem cell genome editing
Ehrke-Schulz et al. CRISPR/Cas9 delivery with one single adenoviral vector devoid of all viral genes
Di Matteo et al. Recent developments in transposon-mediated gene therapy
JP2025170240A5 (enExample)
JP2021518139A5 (enExample)
JP2019115348A5 (enExample)
JP2022546608A5 (enExample)
US20180163188A1 (en) Engineering of a minimal SaCas9 CRISPR/Cas system for gene editing and transcriptional regulation optimized by enhanced guide RNA
HK1223401A1 (zh) 用於治疗遗传病状的方法和组合物
JP2022519595A5 (enExample)
JP2022516130A5 (enExample)
JP2023533417A5 (enExample)
IL295858B1 (en) gRNA molecules including TRACR and crRNA, compositions containing them and their use
JP2018516978A5 (enExample)
JP2021521849A5 (enExample)
JP2021520800A5 (enExample)
US20190241911A1 (en) Engineered guide rna and uses thereof
CN113195001B (zh) 重组细小病毒载体及其制备方法和用途
JP2021502077A5 (enExample)
JP7765377B2 (ja) Huhエンドヌクレアーゼを用いた標的化ゲノム修飾を促進するための方法及び組成物
JP2020511931A5 (enExample)